Skip to main content
logo
Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
32.60
+2.29 (7.56%)
At close: Oct 5, 2026, 4:00 PM EDT
32.87
+0.27 (0.83%)
Pre-market: Oct 6, 2026, 8:28 AM EDT

Schrödinger Revenue by Type

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Software Products and Services
178.24M186.24M199.50M209.92M200.94M195.80M180.40M169.40MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Software Products and Services Growth
-11.30%-4.88%10.59%23.92%20.74%22.09%13.34%22.52%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Drug Discovery
77.43M68.66M56.37M47.12M37.06M34.77M27.22M24.02MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Drug Discovery Growth
108.96%97.47%107.09%96.16%8.10%23.37%-52.72%-60.67%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Contributions
3.36M-------UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Software Products and Services Revenue Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022
Software Products and Services
21.30M26.88M27.51MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Software Products and Services Growth
-21.45%-2.04%1.09%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Drug Discovery
12.30M11.71M12.98MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Drug Discovery Growth
-4.45%8.73%63.40%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Software Contribution
-12.14M15.99M18.18M16.37M11.86M8.02M3.12M1.80MUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade---
Software Contribution Growth
-2.39%99.45%481.91%809.61%558.89%345.33%73.56%-UpgradeUpgradeUpgradeUpgradeUpgradeUpgrade---

Drug Discovery Revenue Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Drug Discovery Services Customer Contracts
76.46M67.40M54.76M45.32M35.12M32.69M25.14M21.97MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Drug Discovery Services Customer Contracts Growth
117.71%106.21%117.79%106.30%10.16%27.64%-54.05%-62.27%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Drug Discovery Contribution
1.42M1.26M1.61M1.76M1.89M2.04M2.03M2.02MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Drug Discovery Contribution Growth
-24.81%-38.30%-20.78%-13.29%-20.12%-19.95%-28.03%-29.72%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Revenue by Geography

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
United States
158.18M154.71M152.96M131.30M124.59M121.24M114.87M133.14MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
United States Growth
26.97%27.61%33.16%-1.39%-12.05%-10.14%-29.08%-8.89%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
EMEA
71.98M72.25M75.16M91.28M80.70M81.54M65.65M33.86MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
EMEA Growth
-10.81%-11.39%14.49%169.56%148.50%176.37%125.33%22.28%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
APAC
27.60M26.78M26.18M32.70M31.23M26.38M25.80M25.18MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
APAC Growth
-11.64%1.54%1.47%29.87%22.62%14.69%5.02%-19.14%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Rest of World
1.27M1.16M1.56M1.67M1.40M1.35M1.22M1.16MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Rest of World Growth
-9.01%-13.53%28.16%44.18%35.43%25.94%21.68%-UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade